Search

Aron David Thall

from San Diego, CA
Age ~64
Get Report
Also known as:
Aron D Thall, Araon D Thall, Aaron Thall, Thall D Aron
Phone and address:
14381 Bourgeois Way, San Diego, CA 92129
(858) 484-1056
Related to:
Brandon ThallNancy Betz, 60Cameron Thall, 35Joshua Thall, 30Robert Thall, 59
Connected to:
Girish K Thallapragada, 46Stacy A Thallas, 65Melissa H Thallemer, 47Christina E Thaller, 78Fred D Thaller, 71Jan L Thaller, 65Joye A Thaller, 49Patrick W Thaller, 80Allison R Thalley, 60William L Thalley, 44

Aron Thall Phones & Addresses

  • 14381 Bourgeois Way, San Diego, CA 92129 (858) 484-1056
  • Bourgeois Way, San Diego, CA 92129 (858) 484-0246
  • Kalamazoo, MI
  • 24 Holly Ln, Beverly, MA 01915 (978) 524-4854
  • Los Alamitos, CA
  • Ann Arbor, MI

Work

Position: Professional/Technical

Education

Degree: Associate degree or higher

Resumes

Resumes

Aron Thall Photo 1

Global Clinical Lead

View page
Location:
San Diego, CA
Work:
Pfizer
Global Clinical Lead
Aron Thall Photo 2

Oncology Clinician

View page
Position:
Clinician-Oncology at Pfizer
Location:
Greater San Diego Area
Industry:
Biotechnology
Work:
Pfizer - La Jolla, CA since Jan 2008
Clinician-Oncology
Education:
University of California, San Francisco 1986 - 1990
PhD, Cell Biology

Publications

Us Patents

Pd-1/Pd-L1 Inhibitors For Cancer Treatment

View page
US Patent:
20190144545, May 16, 2019
Filed:
May 22, 2017
Appl. No.:
16/304338
Inventors:
- Darmstadt, DE
- New York NY, US
Adrian WOOLFSON - Brooklyn NY, US
Aron THALL - San Diego CA, US
Kevin CHIN - Sudbury MA, US
Satjit BRAR - San Diego CA, US
Assignee:
MERCK PATENT GMBH - Darmstadt
PFIZER INC. - New York NY
International Classification:
C07K 16/28
A61P 35/04
Abstract:
The invention relates to methods of treating cancer in a subject, comprising administering to the subject a therapeutically effective amount of an inhibitor of the interaction between the PD-1 receptor and its ligand PD-L1.

Combination Of An Ox40 Agonist And A 4-1Bb Agonist Monoclonal Antibody For Treating Cancer

View page
US Patent:
20190031765, Jan 31, 2019
Filed:
Jan 17, 2017
Appl. No.:
16/069712
Inventors:
- NEW YORK NY, US
ARON DAVID THALL - SAN DIEGO CA, US
Assignee:
PFIZER INC. - NEW YORK NY
International Classification:
C07K 16/28
A61P 35/00
Abstract:
The present disclosure describes combination therapies comprising an agonist of OX40 and an agonist of 4-1BB, and the use of the combination therapies for the treatment of cancer.

Pd-L1 Antagonist Combination Treatments

View page
US Patent:
20180169232, Jun 21, 2018
Filed:
Jun 15, 2016
Appl. No.:
15/736615
Inventors:
Glen Ian ANDREWS - San Diego CA, US
Shihao CHEN - Foster City CA, US
Alessandra DI PIETRO - Opera, IT
David FONTANA - Clyde Hill WA, US
Zelanna GOLDBERG - San Diego CA, US
Chia-Yang LIN - Palo Alto CA, US
Hua LONG - San Carlos CA, US
Marcella MARTIGNONI - Milan, IT
Dimitry Serge Antotne NUYTEN - San Francisco CA, US
Aron David THALL - San Diego CA, US
Adrian WOOLFSON - New York NY, US
- Darmstadt, DE
- New York NY, US
Assignee:
MERCK PATENT GMBH - Darmstadt
PFIZER INC. - New York NY
International Classification:
A61K 39/395
A61K 31/4439
C07K 16/28
C07K 16/24
A61K 33/24
A61K 31/4184
A61K 31/706
A61P 35/00
Abstract:
The present disclosure describes combination therapies comprising an antagonist of Programmed Death Ligand 1 receptor (PD-L1) and another therapeutic agent, and the use of the combination therapies for the treatment of cancer.
Control profile
Aron David Thall from San Diego, CA, age ~64 Get Report